Pelareorep Plus Atezolizumab Drives Responses in Third-Line Squamous Cell Anal Carcinoma | OncLive Updated data from the GOBLET trial show pelareorep plus atezolizumab achieved a 29% ORR with durable responses in heavily pretreated SCAC.

Pelareorep Plus Atezolizumab Drives Responses in Third-Line Squamous Cell Anal Carcinoma #onoclogy #GIoncology

www.onclive.com/view/pelareo...